| Reviews in Urology | |
| Prevention, Complementary Therapies, and New Scientific Developments in the Field of Prostate Cancer | |
| Philip Kantoff1  | |
| [1] Division of Solid Tumor Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA | |
| 关键词: Prostate cancer; 5a reductase inhibitors; Prostate-specific antigens; Antioxidants; | |
| DOI : | |
| 学科分类:基础医学 | |
| 来源: MedReviews, LLC | |
PDF
|
|
【 摘 要 】
Prostate cancer prevention and therapies were reviewed in a recent update. Finasteride, a 5α reductase inhibitor, shows promise as a preventative; however, it may increase the incidence of high-grade cancer. There are ongoing studies regarding the positive effects of antioxidant therapy (vitamin E, selenium, and lycopene) on the prevention of prostate cancer; initial results are promising. Lipid-lowering drugs are associated with a statistically significant reduction in prostate cancer incidence, a 46% reduction in risk of high-grade or high-stage prostate cancer, and a 66% reduction in mortality from prostate cancer. Overexpression of transcription factors is caused by translocation of the promoter of the TMPRSS2 gene, which may be a primary event in prostate cancer. Immunomic profiling with use of autoantibodies directed against prostate-specific antigens may be used to identify cases of prostate cancer.
【 授权许可】
Unknown
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO201912040560192ZK.pdf | 393KB |
PDF